AI Article Synopsis

  • Carbapenem-Resistant Enterobacteriaceae (CRE) infections are a significant healthcare threat, leading to high rates of illness and death, especially in critically ill patients.
  • Limited treatment options exist due to their multi-drug resistant nature, with potential therapies including carbapenems, polymyxins, and others.
  • The review emphasizes the importance of understanding pharmacokinetics and pharmacodynamics (PK-PD) to enhance the effectiveness of these treatment options for CRE infections.

Article Abstract

Carbapenem-Resistant Enterobacteriaceae (CRE) are an emerging healthcare crisis. Infections due to CRE are associated with high morbidity and mortality, especially in critically ill patients. Due to the multi-drug resistant nature of these infections only limited treatment options are available. Antimicrobials that have been described for the treatment of CRE infections include carbapenems, polymyxins, fosfomycin, tigecycline, aminoglycosides, and ceftazidime-avibactam. Given the limited treatment options it is imperative the pharmacokinetic and pharmacodynamics (PK-PD) characteristics of these agents are considered to optimize treatment regimens. This review will focus on the PK-PD challenges of the current treatment options for CRE infections.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477717PMC
http://dx.doi.org/10.1080/21505594.2016.1221021DOI Listing

Publication Analysis

Top Keywords

treatment options
12
critically ill
8
ill patients
8
carbapenem-resistant enterobacteriaceae
8
limited treatment
8
cre infections
8
treatment
6
pharmacodynamic pharmacokinetic
4
pharmacokinetic considerations
4
considerations treatment
4

Similar Publications

A New Way Forward for Women's Health Research at the National Institutes of Health: A Roadmap From the National Academies of Sciences, Engineering, and Medicine's Consensus Report.

Obstet Gynecol

January 2025

Department of Obstetrics and Gynecology, Spencer Fox Eccles School of Medicine, University of Utah Health, Salt Lake City, Utah; the Department of Obstetrics and Gynecology, Warren Alpert Medical School at Brown University, and Women and Infants Hospital of Rhode Island, Providence, Rhode Island; the National Academies of Sciences, Engineering, and Medicine, and Baker Donelson, Washington, DC; KFF, San Francisco, California; and the Department of Obstetrics and Gynecology, Duke Cancer Institute, Duke School of Medicine, Durham, North Carolina. All authors served on the National Academies Committee as committee members or employees of the National Academies.

Despite efforts to address inequities, research on women's health conditions (defined as those that uniquely or differently affect women and female individuals) remain significantly understudied. As directed by Congress, the National Institutes of Health (NIH) Office of Research on Women's Health requested the National Academies of Sciences, Engineering, and Medicine (National Academies) to conduct an assessment of the state of women's health research at the NIH. The findings of the National Academies committee include: 1) a significant funding inequity, with less than 8% of the total NIH grant budget for fiscal year 2023 allocated to women's health research; 2) a need for improved strategic NIH-wide priority setting, oversight, and adherence to existing policies to support women's health research; 3) a need for a specific institute for research on conditions specific to women's health; and 4) a need for sufficient training and additional funding to grow and retain the women's health research workforce.

View Article and Find Full Text PDF

Background: The Wound Care Collaborative Community (WCCC) assesses shortcomings and unmet needs in wound care by partnering with key stakeholders, such as the National Institutes of Health, the US Food and Drug Administration (FDA), industry leaders, and expert health care providers and researchers, to advance the study of wound healing. Through this work, the WCCC has identified a few key barriers to innovation in wound care. The WCCC aims to accelerate the development of science-based, patient-centered solutions and address public policy challenges related to ensuring patients receive early access to innovative treatment options.

View Article and Find Full Text PDF

Simultaneous Lefort 2 Distraction and Fronto-Orbito-Malar Advancement: Correcting Severe Upper and Midface Retrusion in a Patient With Crouzon Syndrome.

J Craniofac Surg

December 2024

Member of Sociedad Argentina de Ortodoncia, Member of International Society of Craneofacial Surgery, Member of Asociación Latinoamericana de Ortodoncia, Buenos Aires, Argentina.

Craniofacial syndromes present with exorbitism and airway obstruction as a result of upper and middle facial hypoplasia. Classical subcranial Lefort III (LF III) or monobloc distraction osteogenesis (DO) using an external craniofacial device is used to treat these deformities. These procedures are done during mixed dentition, in most cases, advancing an abnormal face, to a more normal position.

View Article and Find Full Text PDF

Background And Objectives: The Chordate System administers kinetic oscillation stimulation (K.O.S) into the nasal cavity thereby potentially modulating the activity of trigemino-autonomic reflex.

View Article and Find Full Text PDF

Purpose: Less than 5% of GI stromal tumors (GISTs) are driven by the loss of the succinate dehydrogenase (SDH) complex, resulting in a pervasive DNA hypermethylation pattern that leads to unique clinical features. Advanced SDH-deficient GISTs are usually treated with the same therapies targeting KIT and PDGFRA receptors as those used in metastatic GIST. However, these treatments display less activity in the absence of alternative therapeutic options.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!